Experts analyze adjuvant therapy based on preoperative responses. The discussion unveils standard practices, recent KATHERINE trial data, and considerations for residual disease, offering profound insights into tailoring treatment for improved outcomes.
Health care professionals review considerations in transitioning breast cancer patients to the adjuvant setting and discuss response monitoring, treatment tailoring, and the evolving role of imaging.
Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and discuss unmet needs in this patient population. They also describe options for mutation and resistance marker testing to guide treatment selection.
Experts discuss the controversial role of gene expression patterns in Desmoid tumor treatment decisions, highlighting challenges and potential impact on personalized care.
Kristen Peterson, PharmD, BCOP, explores how pharmacists deliver comprehensive education, empower patients, manage side effects, and prioritize outcomes for multiple myeloma care, ensuring quality treatment understanding and adherence.